These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 16128606)
1. Anthrax vaccines: a development update. Little SF BioDrugs; 2005; 19(4):233-45. PubMed ID: 16128606 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of an improved, human anthrax vaccine. Ivins BE; Welkos SL Eur J Epidemiol; 1988 Mar; 4(1):12-9. PubMed ID: 3128450 [TBL] [Abstract][Full Text] [Related]
4. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection. Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820 [TBL] [Abstract][Full Text] [Related]
5. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes. Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664 [TBL] [Abstract][Full Text] [Related]
6. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Skoble J; Beaber JW; Gao Y; Lovchik JA; Sower LE; Liu W; Luckett W; Peterson JW; Calendar R; Portnoy DA; Lyons CR; Dubensky TW Infect Immun; 2009 Apr; 77(4):1649-63. PubMed ID: 19168734 [TBL] [Abstract][Full Text] [Related]
7. Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Peachman KK; Rao M; Alving CR; Burge R; Leppla SH; Rao VB; Matyas GR Infect Immun; 2006 Jan; 74(1):794-7. PubMed ID: 16369043 [TBL] [Abstract][Full Text] [Related]
8. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913 [TBL] [Abstract][Full Text] [Related]
9. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760 [TBL] [Abstract][Full Text] [Related]
10. Advances in the development of next-generation anthrax vaccines. Friedlander AM; Little SF Vaccine; 2009 Nov; 27 Suppl 4():D28-32. PubMed ID: 19837282 [TBL] [Abstract][Full Text] [Related]
11. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Little SF; Ivins BE; Fellows PF; Pitt ML; Norris SL; Andrews GP Vaccine; 2004 Jan; 22(3-4):422-30. PubMed ID: 14670324 [TBL] [Abstract][Full Text] [Related]
12. BclA and toxin antigens augment each other to protect NMRI mice from lethal Bacillus anthracis challenge. Köhler SM; Baillie LW; Beyer W Vaccine; 2015 Jun; 33(24):2771-7. PubMed ID: 25917676 [TBL] [Abstract][Full Text] [Related]
13. Recent progress in the development of anthrax vaccines. Kaur M; Bhatnagar R Recent Pat Biotechnol; 2011 Dec; 5(3):148-59. PubMed ID: 22360464 [TBL] [Abstract][Full Text] [Related]
15. Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions. Koehler SM; Buyuk F; Celebi O; Demiraslan H; Doganay M; Sahin M; Moehring J; Ndumnego OC; Otlu S; van Heerden H; Beyer W BMC Vet Res; 2017 Jul; 13(1):220. PubMed ID: 28701192 [TBL] [Abstract][Full Text] [Related]
16. Progress and novel strategies in vaccine development and treatment of anthrax. Chitlaru T; Altboum Z; Reuveny S; Shafferman A Immunol Rev; 2011 Jan; 239(1):221-36. PubMed ID: 21198675 [TBL] [Abstract][Full Text] [Related]
17. Development of anthrax DNA vaccines. Ferrari ME; Hermanson G; Rolland A Curr Opin Mol Ther; 2004 Oct; 6(5):506-12. PubMed ID: 15537052 [TBL] [Abstract][Full Text] [Related]
18. Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives. Adamo R Expert Rev Vaccines; 2014 Jul; 13(7):895-907. PubMed ID: 24867680 [TBL] [Abstract][Full Text] [Related]
19. Characterisation of the immune response to the UK human anthrax vaccine. Baillie L; Hebdon R; Flick-Smith H; Williamson D FEMS Immunol Med Microbiol; 2003 May; 36(1-2):83-6. PubMed ID: 12727370 [TBL] [Abstract][Full Text] [Related]
20. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Singh Y; Ivins BE; Leppla SH Infect Immun; 1998 Jul; 66(7):3447-8. PubMed ID: 9632621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]